|
1
|
Brahimi-Horn C and Pouyssegur J: When
hypoxia signalling meets the ubiquitin-proteasomal pathway, new
targets for cancer therapy. Crit Rev Oncol Hematol. 53:115–123.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Liu Z, Diaz LA, Haas AL and Giudice GJ:
cDNA cloning of a novel human ubiquitin carrier protein. An
antigenic domain specifically recognized by endemic pemphigus
foliaceus autoantibodies is encoded in a secondary reading frame of
this human epidermal transcript. J Biol Chem. 267:15829–15835.
1992.
|
|
3
|
Liu Z, Haas AL, Diaz LA, Conrad CA and
Giudice GJ: Characterization of a novel keratinocyte ubiquitin
carrier protein. J Biol Chem. 271:2817–2822. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Welsh JB, Zarrinkar PP, Sapinoso LM, et
al: Analysis of gene expression profiles in normal and neoplastic
ovarian tissue samples identifies candidate molecular markers of
epithelial ovarian cancer. Proc Natl Acad Sci USA. 98:1176–1181.
2001. View Article : Google Scholar
|
|
5
|
Wagner KW, Sapinoso LM, El-Rifai W, et al:
Overexpression, genomic amplification and therapeutic potential of
inhibiting the UbcH10 ubiquitin conjugase in human carcinomas of
diverse anatomic origin. Oncogene. 23:6621–6629. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Rhodes DR, Yu J, Shanker K, et al:
Large-scale meta-analysis of cancer microarray data identifies
common transcriptional profiles of neoplastic transformation and
progression. Proc Natl Acad Sci USA. 101:9309–9314. 2004.
View Article : Google Scholar
|
|
7
|
Jung CR, Hwang KS, Yoo J, et al: E2-EPF
UCP targets pVHL for degradation and associates with tumor growth
and metastasis. Nat Med. 12:809–816. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Harada H, Kizaka-Kondoh S, Li G, et al:
Significance of HIF-1-active cells in angiogenesis and
radioresistance. Oncogene. 26:7508–7516. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ohh M: pVHL’s kryptonite: E2-EPF UCP.
Cancer Cell. 10:95–97. 2006.
|
|
10
|
Tedesco D, Zhang J, Trinh L, et al: The
ubiquitin-conjugating enzyme E2-EPF is overexpressed in primary
breast cancer and modulates sensitivity to topoisomerase II
inhibition. Neoplasia. 9:601–613. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chen MF, Lee KD, Lu MS, et al: The
predictive role of E2-EPF ubiquitin carrier protein in esophageal
squamous cell carcinoma. J Mol Med. 87:307–320. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lim JH, Jung CR, Lee CH and Im DS: Egr-1
and serum response factor are involved in growth factors- and
serum-mediated induction of E2-EPF UCP expression that regulates
the VHL-HIF pathway. J Cell Biochem. 105:1117–1127. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Roos FC, Evans AJ, Brenner W, et al:
Deregulation of E2-EPF ubiquitin carrier protein in papillary renal
cell carcinoma. Am J Pathol. 178:853–860. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Birle DC and Hedley DW: Suppression of the
hypoxia-inducible factor-1 response in cervical carcinoma
xenografts by proteasome inhibitors. Cancer Res. 67:1735–1743.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wu T, Merbl Y, Huo Y, Gallop JL, Tzur A
and Kirschner MW: UBE2S drives elongation of K11-linked ubiquitin
chains by the anaphase-promoting complex. Proc Natl Acad Sci USA.
107:1355–1360. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Garnett MJ, Mansfeld J, Godwin C, et al:
UBE2S elongates ubiquitin chains on APC/C substrates to promote
mitotic exit. Nat Cell Biol. 11:1363–1369. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Pugh CW and Ratcliffe PJ: Regulation of
angiogenesis by hypoxia: role of the HIF system. Nat Med.
9:677–684. 2003. View Article : Google Scholar : PubMed/NCBI
|
